These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17697394)

  • 1. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea.
    Tanaka M; Kobayashi D; Murakami Y; Ozaki N; Suzuki T; Iwata N; Haraguchi K; Ieiri I; Kinukawa N; Hosoi M; Ohtani H; Sawada Y; Mine K
    Int J Neuropsychopharmacol; 2008 Mar; 11(2):261-7. PubMed ID: 17697394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome.
    Murata Y; Kobayashi D; Imuta N; Haraguchi K; Ieiri I; Nishimura R; Koyama S; Mine K
    J Clin Psychopharmacol; 2010 Feb; 30(1):11-7. PubMed ID: 20075642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine.
    Sugai T; Suzuki Y; Sawamura K; Fukui N; Inoue Y; Someya T
    Pharmacogenomics J; 2006; 6(5):351-6. PubMed ID: 16534507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe sleepiness and excess sleep duration induced by paroxetine treatment is a beneficial pharmacological effect, not an adverse reaction.
    Murata Y; Kamishioiri Y; Tanaka K; Sugimoto H; Sakamoto S; Kobayashi D; Mine K
    J Affect Disord; 2013 Sep; 150(3):1209-12. PubMed ID: 23809402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of 5-HT3B Receptor Gene Polymorphisms with the Efficacy of Ondansetron for Postoperative Nausea and Vomiting.
    Kim MS; Lee JR; Choi EM; Kim EH; Choi SH
    Yonsei Med J; 2015 Sep; 56(5):1415-20. PubMed ID: 26256989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
    Gunasekara NS; Noble S; Benfield P
    Drugs; 1998 Jan; 55(1):85-120. PubMed ID: 9463792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paroxetine and galactorrhea.
    Bonin B; Vandel P; Sechter D; Bizouard P
    Pharmacopsychiatry; 1997 Jul; 30(4):133-4. PubMed ID: 9271780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events after the abrupt discontinuation of paroxetine.
    Dominguez RA; Goodnick PJ
    Pharmacotherapy; 1995; 15(6):778-80. PubMed ID: 8602387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
    Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
    Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withdrawal syndromes after paroxetine and sertraline discontinuation.
    Fava GA; Grandi S
    J Clin Psychopharmacol; 1995 Oct; 15(5):374-5. PubMed ID: 8830071
    [No Abstract]   [Full Text] [Related]  

  • 11. Spotlight on paroxetine in psychiatric disorders in adults.
    Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
    CNS Drugs; 2002; 16(6):425-34. PubMed ID: 12027788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Judge might reopen GSK paroxetine case.
    Dyer C
    BMJ; 2016 Feb; 352():i800. PubMed ID: 26858261
    [No Abstract]   [Full Text] [Related]  

  • 13. Higher plasma 5-hydroxyindoleacetic acid levels are associated with SSRI-induced nausea.
    Ueda N; Yoshimura R; Shinkai K; Sakata Y; Nakamura J
    Neuropsychobiology; 2003; 48(1):31-4. PubMed ID: 12886038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients.
    Suzuki Y; Sawamura K; Someya T
    Neuropsychopharmacology; 2006 Apr; 31(4):825-31. PubMed ID: 16205777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
    Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.
    Kelly CM; Juurlink DN; Gomes T; Duong-Hua M; Pritchard KI; Austin PC; Paszat LF
    BMJ; 2010 Feb; 340():c693. PubMed ID: 20142325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment.
    Judge R; Parry MG; Quail D; Jacobson JG
    Int Clin Psychopharmacol; 2002 Sep; 17(5):217-25. PubMed ID: 12177584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Syndrome of inappropriate secretion of anti-diuretic hormone in an elderly depressive patient receiving paroxetine: a case report.
    Suwa A; Wakeno M; Tajika A; Kato M; Sugimoto T; Nishida K; Sakai S; Fujiyama Y; Takekita Y; Kinoshita T
    Int J Geriatr Psychiatry; 2010 Apr; 25(4):433-4. PubMed ID: 20222083
    [No Abstract]   [Full Text] [Related]  

  • 19. Serotonin transporter polymorphism and bleeding time during SSRI therapy.
    Hougardy DM; Egberts TC; van der Graaf F; Brenninkmeijer VJ; Derijks LJ
    Br J Clin Pharmacol; 2008 May; 65(5):761-6. PubMed ID: 18279474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective serotonin reuptake inhibitor. Discontinuation syndrome.
    Finfgeld DL
    J Psychosoc Nurs Ment Health Serv; 2002 Dec; 40(12):14-8. PubMed ID: 12491870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.